BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

As targeted protein degradation grows up, the field is going after harder targets and new mechanisms of action. Over the last year, a series of Phase I/II readouts from front-runner Arvinas Inc. (NASDAQ:ARVN),...
BioCentury | Oct 19, 2020
Finance

How Nimbus’ focus on internal pipeline could point to long-awaited exit

With a new $60 million crossover round and an internal pipeline moving through the clinic, computational chemistry company Nimbus may be nearing a liquidity event for investors who have stuck with the...
BioCentury | Jul 13, 2020
Finance

BeiGene’s billions to support new launches, deep pipeline

By enriching its coffers with a further $2.1 billion from existing shareholders, BeiGene gains a formidable cash position as it brings to market a handful of products in the U.S. and China and advances a...
BioCentury | Jun 27, 2020
Product Development

BARDA no longer funding immunomodulators as support for the therapeutic class to treat COVID-19 grows

A slew of therapies entered the clinic this week aimed at tamping down the immune system to treat excessive lung inflammation in COVID-19 patients, even as BARDA announced it would no longer fund the class...
BioCentury | May 22, 2020
Emerging Company Profile

With $60M, Canaan-incubated Day One seizes on under-appreciated advances in pediatric cancers

Day One is using its $60 million series A round to acquire and develop cancer therapies that target biology shared by pediatric and adult cancers, capitalizing on growing understanding and clinical trial infrastructure to make...
BioCentury | Apr 9, 2020
Finance

As Tango moves toward clinic with $60M series B, another partnership could precede IPO

Although synthetic lethality company Tango’s $60 million series B round includes crossover investors who might normally signal that an IPO is in the offing, President and CEO Barbara Weber thinks the wealth of targets that...
BioCentury | Mar 13, 2020
Tools & Techniques

How to feed the machine: lessons from an AI antibiotics study

The recent AI-based discovery of broad-spectrum antibiotic candidates highlights the potential of new machine learning methods to find compounds humans might otherwise miss, but ups the ante on the quality and diversity of input data...
BioCentury | Jan 22, 2020
Finance

HepaRegeniX aims to bring liver program into clinic with €11M insider round

With €11 million ($12.2 million) in fresh series B funding from insiders, liver regeneration company HepaRegeniX hopes to have a first-in-class molecule in the clinic by fall 2020. Participating in the round were Boehringer Ingelheim...
BioCentury | Jan 14, 2020
Company News

Treadwell emerges with two clinical cancer compounds, $27M seed from Tio

Cancer play Treadwell debuted Monday as Tio Bioventures’s first portfolio company with $27 million in seed funding and a pair of differentiated oral small molecules that are already in the clinic. Founded last year, Tio...
BioCentury | Jan 2, 2020
Company News

Jan. 3 Company Quick Takes: Illumina, PacBio call off deal; plus Innovax, Innate, J&J-Pulmatrix, Intrexon, Janssen-Provention

Illumina ends pursuit of PacBio Illumina Inc. (NASDAQ:ILMN) has terminated its $1.2 billion bid for Pacific Biosciences of California Inc. (NASDAQ:PACB) due to “continued uncertainty of the ultimate outcome,” more than a year after proposing...
Items per page:
1 - 10 of 476